207_Combined course Presentations

Is there a role for thoracic RT in ED-SCLC ? CREST trial

Overall Survival

 Progression was less likely to occur in patients treated with thoracic RT ( PFS @ 6 months = 24% vs 7%, p = 0.001 )

OS @ 1 year: 33% vs 28% (p = 0.06) OS @ 2 years: 13% vs 3% (p = 0.004)

 No differences in grade 3 or higher toxic effects

 Many patients have relapse outside the thorax and the brain

 Thoracic RT in addition to PCI should be considered for all ED- SCLC patients who respond to chemotherapy

Slotman B. et al. Lancet 2015;385